Baum RP, Prasad V, Müller D, Schuchardt C, Orlova A, Wennborg A, Tolmachev V, Feldwisch J

(2010) Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using

synthetic 111In-or 68Ga-labeled affibody molecules. J Nucl Med 51(6):892–897

Bombardieri E, Giammarile F, Aktolun C, Baum RP, Delaloye AB, Maffioli L, Moncayo R,

Mortelmans

L,

Pepe

G,

Reske

SN,

Castellani

MR

(2010)

131

I/123

I-Metaiodobenzylguanidine (mIBG) scintigraphy: procedure guidelines for tumour imaging.

Eur J Nucl Med Mol Imaging 37(12):2436–2446

Deb N, Goris M, Trisler K et al (1996) Treatment of hormone-refractory prostate cancer with

90Y-CYT-356 monoclonal antibody. Clin Cancer Res 2:1289–1297

Decarolis B, Schneider C, Hero B, Simon T, Volland R, Roels F, Dietlein M, Berthold F, Schmidt

M (2013) Iodine-123 metaiodobenzylguanidine scintigraphy scoring allows prediction of out-

come in patients with stage 4 neuroblastoma: results of the Cologne interscore comparison

study. J Clin Oncol 31(7):944–951

French S, DuBois SG, Horn B, Granger M, Hawkins R, Pass A, Plummer E, Matthay K (2013)

131I-MIBG followed by consolidation with busulfan, melphalan and autologous stem cell

transplantation for refractory neuroblastoma. Pediatr Blood Cancer 60(5):879–884

Gabriel M, Decristoforo C, Kendler D, Dobrozemsky G, Heute D, Uprimny C, Kovacs P, Von

Guggenberg E, Bale R, Virgolini IJ (2007) 68Ga-DOTA-Tyr3-octreotide PET in neuroendo-

crine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 48(4):

508–518

Haberkorn U, Giesel F, Morgenstern A et al (2017) The future of radioligand therapy: α, β, or both?

J Nucl Med 58:1017–1018

Haug A, Auernhammer CJ, Wängler B, Tiling R, Schmidt G, Göke B, Bartenstein P, Pöpperl G

(2009) Intraindividual comparison of 68 Ga-DOTA-TATE and 18 F-DOPA PET in patients

with well-differentiated metastatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging

36(5):765–770

Heck MM, Tauber R, Schwaiger S, Retz M, D’Alessandria C, Maurer T et al (2019) Treatment

outcome, toxicity, and predictive factors for Radioligand therapy with (177)Lu-PSMA-I&T in

metastatic castration-resistant prostate cancer. Eur Urol 75:920–926. https://doi.org/10.1016/j.

eururo.2018.11.016

Hofman MS, Emmett L, Sandhu S, Iravani A et al (2021) [177Lu]Lu-PSMA-617 versus cabazitaxel

in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-

label, phase 2 trial. Lancet 397(10276):797–804

Jain TK, Parihar AS, Sood A, Basher RK, Bollampally N, Shekhawat AS, Mittal BR (2018) Orbital

metastasis: rare initial presentation of an occult gall bladder carcinoma. Clin Nucl Med 43(3):

188–189

Kolstad A, Illidge T, Bolstad N et al (2020) Phase 1/2a study of 177Lu-lilotomab satetraxetan in

relapsed/refractory indolent non-Hodgkin lymphoma. Blood Adv 4(17):4091–4101

Kraeber-Bodéré F, Barbet J, Chatal J (2016) Radioimmunotherapy: from current clinical success to

future industrial breakthrough? J Nucl Med 57(3):329–331

Kratochwil C, Giesel FL, Bruchertseifer F et al (2014) 213Bi-DOTATOC receptor-targeted alpha-

radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a

first-inhuman experience. Eur J Nucl Med Mol Imaging 41:2106–2119

Kratochwil C, Giesel FL, Eder M, Afshar-Oromieh A, Benesova M, Mier W et al (2015) [(1)(7)(7)

Lu]Lutetium-labelled PSMA ligand induced remission in a patient with metastatic prostate

cancer. Eur J Nucl Med Mol Imaging 42:987–988. https://doi.org/10.1007/s00259-014-2978-1

Kratochwil C, Flechsig P, Lindner T et al (2019) 68Ga-FAPI PET/CT: tracer uptake in 28 different

kinds of cancer. J Nucl Med 60(6):801–805

Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, Feelders RA,

van Aken MO, Krenning EP (2008) Treatment with the radiolabeled somatostatin analog

[177Lu-DOTA0, Tyr3] octreotate: toxicity, efficacy, and survival. J Clin Oncol 26(13):

2124–2130

7

Precision Radiomolecular Oncology: Challenging the Classical Statistical. . .

107